MEDICAL UPDATE: CMV Retinitis Retreatment Trial

MEDICAL UPDATE: CMV Retinitis Retreatment Trial

Being Alive; February 1994
Mark Katz MD and reported by Jim Stoecker

SOCA (Studies of the Ocular Complications of AIDS) has announced a CMV retinitis retreatment trial. This is for patients with CMV retinitis who have been treated for at least one month within the past month with either ganciclovir or foscarnet and who still have active disease. Participants will be randomized to receive high-dose ganciclovir or high-dose foscarnet or a combination of these two drugs. For information, call Lesley Macarthur at the Jules Stein Eye Clinic, 310.206.4720.

940201
BA940204

AEGiS is made possible through unrestricted grants from Roxane Laboratories, the National Library of Medicine, and donations from users like you. Always watch for outdated information. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1994 - Beings Alive. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. Being Alive, 621 N. San Vicente Blvd., West Hollywood, CA 90069, Tel - 310.289.2551; FAX - 310.289.9866; Email: BeiAlive@aol.com http://www.beingalivela.org/

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1994. AEGIS.